APOB and liver disorder: Our goals were to determine whether treatment with a liver specific ACCi, firsocostat (32), which has been reported to increase plasma TGs and variably to increase apoB concentrations, are associated with altered LDL-apoB particle production rate or half-life (clearance), whether the stage of liver disease alters the LDL-apoB kinetic response to ACCi therapy and whether concurrent treatment with a fibrate can prevent changes in LDL-apoB kinetics.